Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentforFaDuCells(HypopharyngealCarcinomaCells)
- Proprietarycationiclipidsformulation
- HightransfectionefficiencyofsmallRNA(siRNA,shRNA,miRNA),mRNA,pDNA
- Effectiveandrobustintracellulardelivery
- KitincludesTransfectionEnhancerreagent
- Work inthepresenceofserum
- Aprovenreagentforestablishingstablecelllines
- Optimizedtransfectionprotocolsareadaptedforusewithbothstandard&reversetransfectionmethods
- DownloadFaDutransfectionprotocol:[PDF]
- Download FaDuCRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforFaDu cellstransfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast70%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsFaDuTransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
FaDu CellLine:
Hypopharyngealcancerisadiseasewherecancerouscellsdevelopinthelowerpartofthethroat,particularlyintheliningofthehypopharynx,whichisusuallydetectedatanadvancedstagebecauseoftheabsenceofearlysymptoms.AccordingtotheresearchersatHarvardMedicalSchool,peoplewhosmokeandhaveavitaminAdeficiencyaremorelikelytodeveloppharyngealcancer,orasitiscommonlyknown,throatcancer.Transfectionstudiescarriedoutviacancercelllinescanhelpdeterminenovelbiochemicalpathwaysthatcanretardthegrowthofcanceroustumors.TheFaDuthroatcancercelllinewasderivedfromahypopharyngealtumorofa56-yearoldHindiCaucasianmale.FaDucelllineshavebeenknowntoproduceproinflammatorycytokinesandactivateneutrophilsinvitro,alongwithHT-29cellline.InadditiontobeinganappropriatetransfectionhostforvariouscellularandmolecularBIOLOGyapplications,theFaDucelllineiscommonlyutilizedinthestudyofpharyngealsquamous-cellcarcinoma.AltogenBiosystemsofferslipid-basedhigh-efficiencytransfectionreagentkitsfortheFaDuhypopharyngealcarcinomacellline.
Data:
Figure1.CyclophilinBsilencingefficiencywasdeterminedbyqRT-PCRin FaDucellstransfectedbyCyclophilinBsiRNAornon-silencingsiRNAcontrolfollowingtherecommendedtransfectionprotocol.CyclophilinmRNAexpressionlevelsweremeasured48hourspost-transfection.18SrRNAlevelswereusedtonormalizetheCyclophilinBdata.Valuesarenormalizedtountreatedsample.Dataarepresentedasmeans±SD(n=6).
Figure2.ProteinexpressionofCyclophilinBinFaDucells.DNAplasmidexpressingCyclophilinBorsiRNAtargetingCyclophilinBweretransfectedintoFaDucellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
FaDuTransfectionKit
AltogenBiosystems:
AltogenBiosystemsprovidespre-optimizedtransfectionkitsandelectroporationproductsforlifescienceresearch.Transfectionproductsaredevelopedforindividualcancercelllineandtransfectionprotocolsareoptimizedtoenablehightransfection efficiencyofbiomolecules.AltogenBiosystemsdevelopedinvivodeliveryproductsforsmallanimalresearch,mouseandrattargetedtissuedelivery:livertargeted,pancreastargeted,kidneytargeted,PEG-Liposome-,Nanoparticle-,Lipid-,andPolymer-basedinvivotransfectionkits.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofbiomolecules.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BiologyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#1753)
- 1.5ml(Catalog#1754)
- 1.5mlCRISPR(Catalog#2141)
- 8.0ml(Catalog#7039)